Literature DB >> 14709374

Increased circulating malondialdehyde-modified LDL in the patients with familial combined hyperlipidemia and its relation with the hepatic lipase activity.

Kenya Yamazaki1, Hideaki Bujo, Kouichi Taira, Naohiro Itou, Manabu Shibasaki, Kazuo Takahashi, Yasushi Saito.   

Abstract

Familial combined hyperlipidemia (FCHL) is characterized by elevated levels of serum total cholesterol (TC), triglyceride (TG), or both. The increased incidence of coronary artery diseases (CAD) in the patients with FCHL is believed to be caused by circulating atherogenic lipoproteins associated with the complex phenotype. Recent establishment of sensitive detection system for malondialdehyde-modified (MDA)-LDL, which is one of oxidized lipoproteins, showed its increased circulating level in the patients with CAD. In order to know the atherogenic lipoproteins resulted from the dyslipidemia observed in FCHL, we measured the serum MDA-LDL level in the patients. The circulating MDA-LDL level and the ratio of MDA-LDL and LDL-C in FCHL were significantly higher (P<0.05) than those in control, which are adjusted about the age, serum TC, LDL-C and HDL-C levels, respectively. Furthermore, the circulating MDA-LDL level and the ratio of MDA-LDL and LDL-C were negatively correlated (R=-0.635, P<0.01 and R=-0.702, P<0.01, respectively) with hepatic lipase (HL) activity in FCHL. The serum MDA-LDL level and the ratio of MDA-LDL and LDL-C were in the subjects with T/T genotypes in the HL C-514T polymorphism were significantly increased compared to those with C/C genotype, respectively. The subjects with T/T genotype showed the activities to 65 and 79% of those in the subjects with C/C genotype in male and female, respectively. The intima-media thickness (IMT) of carotid artery was significantly higher (P<0.05) in the subjects with T/T genotype than those with C/C genotype in male. These findings indicate that the circulating MDA-LDL level is possibly contributing the atherogenic process in FCHL, and the common HL polymorphism might be a determinant of the serum level of oxidized LDL in the patients with FCHL.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14709374     DOI: 10.1016/j.atherosclerosis.2003.05.001

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  9 in total

1.  Development of capture assays for different modifications of human low-density lipoprotein.

Authors:  Gabriel Virella; M Brooks Derrick; Virginia Pate; Charlyne Chassereau; Suzanne R Thorpe; Maria F Lopes-Virella
Journal:  Clin Diagn Lab Immunol       Date:  2005-01

2.  The levels of MDA-LDL in circulating immune complexes predict myocardial infarction in the VADT study.

Authors:  Maria F Lopes-Virella; Kelly J Hunt; Nathaniel L Baker; Gabriel Virella; Thomas Moritz
Journal:  Atherosclerosis       Date:  2012-08-21       Impact factor: 5.162

3.  LOX-1 ligands containing apolipoprotein B and carotid intima-media thickness in middle-aged community-dwelling US Caucasian and Japanese men.

Authors:  Tomonori Okamura; Akira Sekikawa; Tatsuya Sawamura; Takashi Kadowaki; Emma Barinas-Mitchell; Rachel H Mackey; Aya Kadota; Rhobert W Evans; Daniel Edmundowicz; Aya Higashiyama; Yasuyuki Nakamura; Robert D Abbott; Katsuyuki Miura; Akira Fujiyoshi; Yoshiko Fujita; Yoshitaka Murakami; Naomi Miyamatsu; Akemi Kakino; Hiroshi Maegawa; Kiyoshi Murata; Minoru Horie; Kenichi Mitsunami; Atsunori Kashiwagi; Lewis H Kuller; Hirotsugu Ueshima
Journal:  Atherosclerosis       Date:  2013-04-30       Impact factor: 5.162

4.  Human monoclonal Fab and human plasma antibodies to carbamyl-epitopes cross-react with malondialdehyde-adducts.

Authors:  Outi Kummu; S Pauliina Turunen; Piotr Prus; Jaakko Lehtimäki; Marja Veneskoski; Chunguang Wang; Sohvi Hörkkö
Journal:  Immunology       Date:  2014-03       Impact factor: 7.397

5.  Atorvastatin induces associated reductions in platelet P-selectin, oxidized low-density lipoprotein, and interleukin-6 in patients with coronary artery diseases.

Authors:  Hiroyuki Oka; Satoshi Ikeda; Seiji Koga; Yoshiyuki Miyahara; Shigeru Kohno
Journal:  Heart Vessels       Date:  2008-07-23       Impact factor: 2.037

6.  Functional Haplotype of LIPC Induces Triglyceride-Mediated Suppression of HDL-C Levels According to Genome-Wide Association Studies.

Authors:  Yu-Huang Liao; Leay-Kiaw Er; Semon Wu; Yu-Lin Ko; Ming-Sheng Teng
Journal:  Genes (Basel)       Date:  2021-01-22       Impact factor: 4.096

7.  LIPC variants as genetic determinants of adiposity status, visceral adiposity indicators, and triglyceride-glucose (TyG) index-related parameters mediated by serum triglyceride levels.

Authors:  Ming-Sheng Teng; Semon Wu; Leay-Kiaw Er; Lung-An Hsu; Hsin-Hua Chou; Yu-Lin Ko
Journal:  Diabetol Metab Syndr       Date:  2018-11-06       Impact factor: 3.320

8.  Association between angiopoietin-like protein 2 and lectin-like oxidized low-density lipoprotein receptor 1 ligand containing apolipoprotein B in patients with type 2 diabetes.

Authors:  Tatsuhiko Suzuki; Kohzo Takebayashi; Kenji Hara; Takafumi Tsuchiya; Toshihiko Inukai
Journal:  J Int Med Res       Date:  2018-08-29       Impact factor: 1.671

9.  Pleiotropic association of LIPC variants with lipid and urinary 8-hydroxy deoxyguanosine levels in a Taiwanese population.

Authors:  Ming-Sheng Teng; Semon Wu; Lung-An Hsu; I-Shiang Tzeng; Hsin-Hua Chou; Cheng-Wen Su; Yu-Lin Ko
Journal:  Lipids Health Dis       Date:  2019-05-10       Impact factor: 3.876

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.